AAM
PTGX icon

Advisors Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Advisors Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$489K Sell
4,644
-60
-1% -$5.31K 0.01% 971
2025
Q4 		$411K Sell
4,704
-2
-0% -$164 0.01% 1004
2025
Q3 		$313K Sell
4,706
-18
-0.4% -$1.02K 0.01% 1052
2025
Q2 		$261K Buy
4,724
+3
+0.1% +$144 ﹤0.01% 1071
2025
Q1 		$228K Buy
4,721
+2,123
+82% +$89K ﹤0.01% 1086
2024
Q4 		$100K Buy
+2,598
New +$113K ﹤0.01% 1223

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Advisors Asset Management's PTGX Position: Q1 2026 in Review

Advisors Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 1.3% in Q1 2026, selling an estimated $5.31K and leaving 4,644 shares worth $489K. The position accounts for 0.01% of the portfolio, ranked #971.

Advisors Asset Management first reported a position in PTGX in Q4 2024 and has held it in 6 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Advisors Asset Management held 4,644 shares of Protagonist Therapeutics worth $489K as of Q1 2026.
  • Advisors Asset Management sold 60 Protagonist Therapeutics shares in Q1 2026, an estimated $5.31K.
  • Protagonist Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q1 2026, its #971 holding.
  • Advisors Asset Management first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.